GILD vs BIIB
GILD and BIIB side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | BIIBBIOGEN INC. |
|---|---|---|
| Market cap | $181.41B | $31.91B |
| P/E (TTM) | 21.6 | 23.2 |
| P/B | 15.34 | 2.16 |
| P/S | 6.2x | 3.2x |
| Dividend yield | 2.21% | — |
| Revenue | $30.46B(TTM) | $9.94B(TTM) |
| Revenue growth (YoY) | 2.4% | 2.2% |
| Net income | -$3.24B(TTM) | $1.37B(TTM) |
| Earnings growth (YoY) | 1672.9% | -20.8% |
| EPS, diluted | $-2.65(TTM) | $9.30(TTM) |
| EBIT margin | 34.0% | 28.7% |
| ROE | 71.9% | 8.7% |
| ROIC | 26.7% | 13.0% |
| Piotroski F | — | 4/9 |
| 1y total return | +32.9% | +50.8% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: GILD frente a BIIB
| Métrica | GILD | BIIB |
|---|---|---|
| Valor final | $25.5K | $8.2K |
| Retorno total | +154.7% | -17.7% |
| CAGR | +9.5% | -1.9% |
| Volatilidad | 25.6% | 41.3% |
| Sharpe | 0.32 | 0.05 |
| Sortino | 0.48 | 0.08 |
| Caída máxima | -30.5% | -72.7% |
Basado en 2600 días de negociación comunes, 2016-05-12 → 2026-09-15 · tasa libre de riesgo 4.11% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)